Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • dsher
    Member
    • Feb 2013
    • 23

    #1

    Comparing metagenomes produces with different sequencing technologies

    Hi all,

    I would like to compare the abundance of my gene(s) of interest across many published metagenomes. Typically we would normalize the number of hits to the gene length and number of sequences (or mbp) to get relative abundances, and perhaps also normalize to the abundance of single-copy core genes to get an estimate of the gene number per genome equivalents. This has been done many times, but to the best of my knowledge all such comparison were between metagenomes sequenced using the same technology (e.g. within the GOS dataset, which is all Sanger).

    My question is, can this approach be extended to compare across metagenomes produced with different sequencing technologies (e.g. compare the relative abundance in a marine metagenome sequenced with Sanger to human gut sample sequenced with Illumina)? Are such comparisons valid between samples with very different sequencing coverage? There must be some intelligent controls one would have to run... any suggestions welcome! Also, if anyone is aware of publications where such comparisons have been performed I would love to hear about them!

    Thanks
    Daniel
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    Originally posted by dsher View Post
    My question is, can this approach be extended to compare across metagenomes produced with different sequencing technologies (e.g. compare the relative abundance in a marine metagenome sequenced with Sanger to human gut sample sequenced with Illumina)? Are such comparisons valid between samples with very different sequencing coverage?
    I'm an author of an upcoming paper that does something along these lines. Generally, I think it's a bad idea to quantify across platforms like that. You will run into a lot of variable GC-related coverage bias, which is nonlinear and hard to compensate for.

    Comment

    • dsher
      Member
      • Feb 2013
      • 23

      #3
      Thanks Brian. Do these difficulties extend also to comparing between different versions of the same sequencing technique (e.g. between HiSeq and MySeq or between HiSeq or 454 versions as they evolve to provide different read lengths)?

      Also, I would really be grateful if you could share the info on this publication (perhaps on this thread?) once it is publically available.

      Cheers
      Daniel

      Comment

      • Brian Bushnell
        Super Moderator
        • Jan 2014
        • 2709

        #4
        Originally posted by dsher View Post
        Thanks Brian. Do these difficulties extend also to comparing between different versions of the same sequencing technique (e.g. between HiSeq and MySeq or between HiSeq or 454 versions as they evolve to provide different read lengths)?
        To be honest, yes, unfortunately - different versions of Illumina chemistry have different GC biases; newer versions tend to have a lower bias than older ones. The read length shouldn't matter, but the chemistry does. I don't know if there is a substantial bias difference between chemistry versions on other platforms (454, Solid, PacBio), and probably some versions of Illumina chemistry are fairly equivalent to other versions and could be compared, but others definitely are not.

        Also, I would really be grateful if you could share the info on this publication (perhaps on this thread?) once it is publically available.
        It will be submitted this week, so hopefully that will be soon!

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
          by SEQadmin2



          Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

          Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
          ...
          10-14-2026, 09:55 AM
        • SEQadmin2
          New Genomics Technologies Take Aim at Long-Standing Limits
          by SEQadmin2


          Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

          We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
          ...
          09-28-2026, 10:25 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 10-22-2026, 11:13 AM
        0 responses
        27 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-22-2026, 10:48 AM
        0 responses
        20 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-15-2026, 10:52 AM
        0 responses
        36 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 10-14-2026, 05:39 AM
        0 responses
        43 views
        0 reactions
        Last Post SEQadmin2  
        Working...